Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Kuvan / sapropterin for treating hyperphenylalaninaemia in phenylketonuria as of September 2021

MARA Rating Company December 16, 2025

Secukinumab / cosentyx for treating non-radiographic axial spondyloarthritis as of July 2021

MARA Rating Company December 16, 2025

Secukinumab / cosentyx for treating moderate to severe plaque psoriasis in children and young people as of October 2021

MARA Rating Company December 16, 2025

Secukinumab / cosentyx for treating moderate to severe hidradenitis suppurativa as of December 2023

MARA Rating Company December 16, 2025

Selinexor for treating relapsed or refractory multiple myeloma after 4 or more treatments as of May 2024

MARA Rating Company December 16, 2025

Rimegepant / vydura for treating migraine as of October 2023

MARA Rating Company December 16, 2025

Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments as of May 2023

MARA Rating Company December 16, 2025

Skyrizi / risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs as of July 2022

MARA Rating Company December 16, 2025

Skyrizi / risankizumab for treating moderately to severely active Crohn’s disease in people 16 years and over as of May 2023

MARA Rating Company December 16, 2025

Skyrizi / risankizumab for treating moderately to severely active ulcerative colitis as of August 2024

MARA Rating Company December 16, 2025